AliceScottMimsMDMSCR

Oncology • Columbus, OH

Hematologic Oncology

Professor, Medicine, The Ohio State University/James Cancer Hospital and Solove Research Institute

Join to view full profile

Dr. Mims is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mims' full profile

Already have an account?

Office
460 W 10th Ave
James 5th Floor
Columbus, OH 43210
Phone+1 614-293-5655

Fax+1 614-293-7526

Summary

Acute leukemias and myeloid malignancies

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2011
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 2005 - 2008
Medical University of South CarolinaClass of 2005

Certifications & Licensure

OH State Medical License 2009 - 2026
SC State Medical License 2012 - 2017
NC State Medical License 2005 - 2012
IA State Medical License 2008 - 2011
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
Completed
Phase 2
A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia Start of enrollment: 2013 Dec 01
Completed
Phase 1
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia Start of enrollment: 2020 Mar 11
Active, not recruiting
Phase 1
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) Start of enrollment: 2022 Sep 13
Recruiting
Phase 2
Roles: Contact, Sponsor-Investigator, Principal Investigator
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH Start of enrollment: 2021 Feb 28
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia Start of enrollment: 2022 Jun 01
Recruiting
Not Applicable
Roles: Contact
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene Start of enrollment: 2024 Nov 10
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

278 citations
Acute myeloid leukemia, version 3.2019
Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt
Journal of the National Comprehensive Cancer Network. 2019-01-01
10 citations
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Evan C. Chen, Shuli Li, Ann-Kathrin Eisfeld, Marlise R. Luskin, Alice S. Mims
Transplantation and Cellular Therapy. 2021-02-25
10 citations
Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination.
Eric D Eisenmann, Dominique A Garrison, Zahra Talebi, Yan Jin, Josie A Silvaroli
Pharmaceutics. 2022-03-23

Journal Articles

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome
Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature

Abstracts/Posters

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patient...
Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Follo...
Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
Alice S. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

New Agents in Myeloid Malignancies
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Ohio State's Novel DHODH Inhibitor Enters First Human TrialsSeptember 16th, 2024
Add-on Venetoclax Promising in Younger, Fit AML PatientsJuly 30th, 2021
Targeted Therapy Approvals Spur Increased Biomarker Research in AMLJanuary 9th, 2020
Join now to see all